New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer

Korean Journal of Urology

Volumn 56, Issue 8, 2015, Pages 553-564

  Ather, M Hammad ^a   Nazim, Syed M ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Biological markers; Cytology; Transitional cell carcinoma; Urinary bladder

Indexed keywords

AURORA A KINASE; CASPASE 3; CYTOKERATIN 20; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; KI 67 ANTIGEN; NITRIC OXIDE SYNTHASE; NUCLEAR MATRIX PROTEIN 22; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TELOMERASE; VASCULOTROPIN; TUMOR MARKER;

BIOPSY; BLADDER CANCER; BLADDER CANCER DETECTION KIT; BLOOD GROUP ABO SYSTEM; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL DECISION MAKING; CYSTOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MICROSATELLITE MARKER; RECURRENCE FREE SURVIVAL; REVIEW; TISSUE MICROARRAY; TRANSURETHRAL RESECTION; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; AGE; CARCINOMA, TRANSITIONAL CELL; DISEASE COURSE; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

AGE FACTORS; BIOMARKERS, TUMOR; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; HUMANS; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

EID: 84938886055     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2015.56.8.553     Document Type: Review

References (86)

1. Colombel M, Soloway M, Akaza H, Bohle A, Palou J, Buckley R, et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol Suppl 2008;7:618-26
2. Karaoglu I, van der Heijden AG, Witjes JA. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. World J Urol 2014;32:651-9
3. Chade DC, Shariat SF, Godoy G, Meryn S, Dalbagni G. Critical review of biomarkers for the early detection and surveillance of bladder cancer. J Mens Health 2009;6:368-82
4. Ha YS, Yan C, Lym MS, Jeong P, Kim WT, Kim YJ, et al. GSTT1 as a prognosticator for recurrence and progression in patients with non-muscle-invasive bladder cancer. Dis Markers 2010;29:81-7
5. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer:a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30
6. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare pay-ments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828-41
7. Chen JX, Deng N, Chen X, Chen LW, Qiu SP, Li XF, et al. A novel molecular grading model:combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer. Asian Pac J Cancer Prev 2012;13:2229-34
8. Matsushita K, Cha EK, Matsumoto K, Baba S, Chromecki TF, Fajkovic H, et al. Immunohistochemical biomarkers for blad-der cancer prognosis. Int J Urol 2011;18:616-29
9. Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. Biomarkers in bladder cancer. BJU Int 2010;105:608-13
10. Habuchi T, Marberger M, Droller MJ, Hemstreet GP 3rd, Grossman HB, Schalken JA, et al. Prognostic markers for blad-der cancer:International Consensus Panel on bladder tumor markers. Urology 2005;66(6 Suppl 1):64-74
11. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder:update 2013. Eur Urol 2013;64:639-53
12. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progres-sion in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-5
13. Zieger K, Wolf H, Olsen PR, Hojgaard K. Long-term follow-up of noninvasive bladder tumours (stage Ta):recurrence and progression. BJU Int 2000;85:824-8
14. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodríguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73-8
15. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164(3 Pt 1):680-4
16. Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal 2006;6:2617-25
17. Kurth KH, Sylvester RJ. Prognostic factors in non-muscle-invasive bladder tumors:I. Clinical prognostic factors:a review of the experience of the EORTC genito-urinary group II. Bio-logic prognostic markers. Eur Urol Suppl 2007;6:789-99
18. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin:multivariate analysis of data from four ran-domized CUETO trials. Eur Urol 2008;53:992-1001
19. Mariappan P, Finney SM, Head E, Somani BK, Zachou A, Smith G, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced sur-geons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer:validation across time and place and recom-mendation for benchmarking. BJU Int 2012;109:1666-73
20. Brausi M, Collette L, Kurth K, van der Meijden AP, Ooster-linck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder:a combined analysis of seven EORTC studies. Eur Urol 2002;41:523-31
21. Faba OR, Palou J, Breda A, Villavicencio H. High-risk non-muscle-invasive bladder cancer:update for a better identifica-tion and treatment. World J Urol 2012;30:833-40
22. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin:the CUETO scoring model. J Urol 2009;182:2195-203
23. Rosevear HM, Lightfoot AJ, Nepple KG, O'Donnell MA. Use-fulness of the Spanish Urological Club for Oncological Treat-ment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α. J Urol 2011;185:67-71
24. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Ojea A, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin:external validation of the EORTC risk tables. Eur Urol 2011;60:423-30
25. Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, et al. Accuracy of the EORTC risk tables and of the CUETO scor-ing model to predict outcomes in non-muscle-invasive urothe-lial carcinoma of the bladder. Br J Cancer 2013;109:1460-6
26. Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int 2010;106:357-61
27. Herr HW. Age and outcome of superficial bladder cancer treat-ed with bacille Calmette-Guérin therapy. Urology 2007;70:65-8
28. Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bas-tian PJ, et al. p53 expression in patients with advanced urothe-lial cancer of the urinary bladder. BJU Int 2010;105:489-95
29. Moonen PM, van Balken-Ory B, Kiemeney LA, Schalken JA, Witjes JA. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol 2007;177:80-3
30. Oh JJ, Ji SH, Choi DK, Gong IH, Kim TH, Park DS. A six-week course of bacillus Calmette-Guérin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53. Oncology 2010; 79:440-6
31. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakie-wicz PI, et al. Predictive value of combined immunohisto-chemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009;182:78-84
32. Schultz IJ, Wester K, Straatman H, Kiemeney LA, Babjuk M, Mares J, et al. Gene expression analysis for the prediction of re-currence in patients with primary Ta urothelial cell carcinoma. Eur Urol 2007;51:416-22
33. Burger M, Denzinger S, Hartmann A, Wieland WF, Stoehr R, Obermann EC. Mcm2 predicts recurrence hazard in stage Ta/ T1 bladder cancer more accurately than CK20, Ki67 and histo-logical grade. Br J Cancer 2007;96:1711-5
34. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transi-tional cell carcinoma. J Urol 2007;177:481-7
35. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90-6
36. Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma:a multicenter validation study. Clin Cancer Res 2007;13:3545-51
37. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, et al. The case for early cystectomy in the treat-ment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006;175(3 Pt 1):881-5
38. Brake M, Loertzer H, Horsch R, Keller H. Recurrence and pro-gression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000;163:1697-701
39. Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for su-perficial bladder cancer. J Urol 2002;167:364-7
40. Cheng L, Montironi R, Davidson DD, Lopez-Beltran A. Stag-ing and reporting of urothelial carcinoma of the urinary blad-der. Mod Pathol 2009;22 Suppl 2:S70-95
41. Orsola A, Trias I, Raventos CX, Espanol I, Cecchini L, Bucar S, et al. Initial high-grade T1 urothelial cell carcinoma:feasi-bility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005;48:231-8
42. Chang WC, Chang YH, Pan CC. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection. Am J Surg Pathol 2012;36:454-61
43. van Rhijn BW, Liu L, Vis AN, Bostrom PJ, Zuiverloon TC, Fleshner NE, et al. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treat-ment of Cancer risk scores in primary T1 bladder cancer. BJU Int 2012;110:1169-76
44. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, et al. Prognostic markers in bladder cancer:a con-temporary review of the literature. J Urol 1998;160(3 Pt 1):645-59
45. Knowles MA. Molecular subtypes of bladder cancer:Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-73
46. van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leen-ders GJ, Ooms BC, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010;58:433-41
47. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, et al. Two molecular pathways to transi-tional cell carcinoma of the bladder. Cancer Res 1994;54:784-8
48. Karam JA, Shariat SF, Hsieh JT, Knowles MA. Genomics:a preview of genomic medicine. BJU Int 2008;102(9 Pt B):1221-7
49. Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stohr R, et al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol 2014;65:218-26
50. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Co-operative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007;20:445-59
51. Goebell PJ, Groshen SG, Schmitz-Drager BJ; International Study-Initiative on Bladder Cancer (ISBC). p53 immunohis-tochemistry in bladder cancer:a new approach to an old ques-tion. Urol Oncol 2010;28:377-88
52. Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Drager BJ, Goebell PJ, et al. Statistical consideration for clinical bio-marker research in bladder cancer. Urol Oncol 2010;28:389-400
53. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, et al. P53 as a prognostic marker for bladder cancer:a meta-analysis and review. Lancet Oncol 2005;6:678-86
54. Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F, et al. Altered p53 and pRb expression is predic-tive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res 2009;29:4201-4
55. Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003;61:1140-5
56. Burton PB, Anderson CJ, Corbishly CM. Caspase 3 and p27 as predictors of invasive bladder cancer. N Engl J Med 2000;343:1418-20
57. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skin-ner DG, et al. Angiogenesis in bladder cancer:relationship be-tween microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603-12
58. Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama HO, Kagawa S. Expression of angiopoietin-1 and-2, and its clinical significance in human bladder cancer. BJU Int 2005;95:660-3
59. van Kessel KE, Kompier LC, de Bekker-Grob EW, Zuiverloon TC, Vergouwe Y, Zwarthoff EC, et al. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance:a comparison of 3 strategies. J Urol 2013;189:1676-81
60. van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol 2012;187:310-4
61. Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status:a prospective study. Eur Urol 2008;54:835-43
62. Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amo-ros A, Tardon A, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24:3664-71
63. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capi-tanio U, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009;101:114-9
64. Chen PC, Yu HJ, Chang YH, Pan CC. Her2 amplification dis-tinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol 2013;66:113-9
65. Sandes EO, Lodillinsky C, Langle Y, Belgorosky D, Marino L, Gimenez L, et al. Inducible nitric oxide synthase and PPARγ are involved in bladder cancer progression. J Urol 2012;188:967-73
66. Yim MS, Ha YS, Kim IY, Yun SJ, Choi YH, Kim WJ. HMOX1 is an important prognostic indicator of nonmuscle invasive blad-der cancer recurrence and progression. J Urol 2011;185:701-5
67. Klatte T, Xylinas E, Rieken M, Kluth LA, Roupret M, Pycha A, et al. Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. J Urol 2014;191:1238-43
68. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007;8:128-36
69. Ding W, Gou Y, Sun C, Xia G, Wang H, Chen Z, et al. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC. Urol Oncol 2014;32:42.e13-9
70. Schmitz-Drager BJ, Todenhofer T, van Rhijn B, Pesch B, Hud-son MA, Chandra A, et al. Considerations on the use of urine markers in the management of patients with low-/intermedi-ate-risk non-muscle invasive bladder cancer. Urol Oncol 2014; 32:1061-8
71. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine bio-markers (FISH, ImmunoCyt, NMP22) and cytology for the de-tection and follow-up of bladder cancer. Health Technol Assess 2010;14:1-331, iii-iv
72. Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, Lotan Y, Shar-iat SF. Urine markers for detection and surveillance of bladder cancer. Urol Oncol 2014;32:222-9
73. Villicana P, Whiting B, Goodison S, Rosser CJ. Urine-based as-says for the detection of bladder cancer. Biomark Med 2009;3:265
74. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance:a systematic review. Eur Urol 2005;47:736-48
75. Fradet Y, Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer:ImmunoCyt trade mark. Can J Urol 1997;4:400-5
76. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detec-tion of human bladder cancer. Urology 1998;52:398-402
77. Olsson H, Zackrisson B. ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carci-noma. Scand J Urol Nephrol 2001;35:280-2
78. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003;169:1975-82
79. Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 2001;58:367-71
80. Zellweger T, Benz G, Cathomas G, Mihatsch MJ, Sulser T, Gas-ser TC, et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006;119:1660-5
81. Ross JS, Cohen MB. Ancillary methods for the detection of recurrent urothelial neoplasia. Cancer 2000;90:75-86
82. Yoder BJ, Skacel M, Hedgepeth R, Babineau D, Ulchaker JC, Liou LS, et al. Reflex UroVysion testing of bladder cancer sur-veillance patients with equivocal or negative urine cytology:a prospective study with focus on the natural history of anticipa-tory positive findings. Am J Clin Pathol 2007;127:295-301
83. Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005;173:401-4
84. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers:meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008;26:646-51
85. Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, et al. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 2008;100:1401-11
86. Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A. Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol 2009;43:461-6